Wipfli Financial Advisors’s Haemonetics HAE Stock Holding History

Wipfli Financial Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$25K	Buy	+336	New	+$24.1K	﹤0.01%	1469

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wipfli Financial Advisors's HAE Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Haemonetics (HAE) in Q3 2022: 336 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #1469 among its holdings.

270 funds tracked by Wall St. Rank hold HAE as of Q3 2022.

Wipfli Financial Advisors held 336 shares of Haemonetics worth $25K as of Q3 2022.
Haemonetics was a new Wipfli Financial Advisors position in Q3 2022.
Haemonetics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1469 holding.
270 funds tracked by Wall St. Rank held Haemonetics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.